Alphatec (ATEC) Set to Post Quarterly Earnings on Thursday

Key Points

• Alphatec is expected to report Q3 2026 results after Thursday’s market close, with analysts forecasting $0.0951 in earnings per share and $225.16 million in revenue.
• In its prior quarter, Alphatec met the $0.07 EPS consensus and exceeded revenue expectations, posting $213.51 million in sales—up 15.1% year over year—despite negative profitability metrics.
• Analyst sentiment is broadly positive, with 13 Buy, one Hold, and one Sell rating and a consensus price target of $17.40, compared with the stock’s recent price of $10.86.

Alphatec (NASDAQ:ATEC - Get Free Report) is expected to release its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to announce earnings of $0.0951 per share and revenue of $225.16 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The medical technology company reported $0.07 EPS for the quarter, meeting the consensus estimate of $0.07. The company had revenue of $213.51 million for the quarter, compared to the consensus estimate of $211.26 million. Alphatec had a negative net margin of 13.49% and a negative return on equity of 6,752.24%. Alphatec's revenue for the quarter was up 15.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.02 EPS. On average, analysts expect Alphatec to post ($0.45) EPS for the current fiscal year and $0.03 EPS for the next fiscal year.

Alphatec Stock Performance

NASDAQ:ATEC opened at $10.86 on Thursday. The firm has a market cap of $1.68 billion, a P/E ratio of -15.30 and a beta of 0.78. Alphatec has a fifty-two week low of $6.82 and a fifty-two week high of $23.29. The firm has a 50-day simple moving average of $10.00 and a two-hundred day simple moving average of $9.39.

Insider Buying and Selling at Alphatec

In related news, General Counsel Tyson Marshall sold 8,168 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $9.65, for a total transaction of $78,821.20. Following the sale, the general counsel directly owned 630,398 shares of the company's stock, valued at $6,083,340.70. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Patrick Miles acquired 115,000 shares of Alphatec stock in a transaction that occurred on Thursday, September 10th. The stock was acquired at an average price of $8.81 per share, with a total value of $1,013,150.00. Following the completion of the acquisition, the chief executive officer directly owned 5,893,551 shares in the company, valued at $51,922,184.31. This represents a 1.99% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 13.48% of the company's stock.

Wall Street Analysts Forecast Growth

ATEC has been the topic of several analyst reports. TD Cowen upped their target price on shares of Alphatec from $11.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Stifel Nicolaus cut their price target on shares of Alphatec from $16.00 to $13.00 and set a "buy" rating on the stock in a report on Wednesday, July 8th. Weiss Ratings reissued a "sell (d-)" rating on shares of Alphatec in a research report on Monday, August 3rd. Wall Street Zen lowered shares of Alphatec from a "buy" rating to a "hold" rating in a report on Sunday, October 11th. Finally, BMO Capital Markets boosted their price objective on shares of Alphatec from $11.00 to $12.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Alphatec presently has an average rating of "Moderate Buy" and a consensus price target of $17.40.

Alphatec Company Profile

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.